Aarti Drugs

Aarti Drugs is a pharmaceutical company with its headquarters located in India.
The firm operates within the pharmaceutical sector, engaging in the research, development, manufacturing, and distribution of medicinal products.
Its headquarters in India places it within a major global market for pharmaceuticals.
Detailed information about the company’s specific product lines, revenue, workforce, or production capacity is not disclosed in the available sources.

The sources do not provide quantitative metrics such as annual turnover, number of employees, or extent of international operations for Aarti Drugs.
Consequently, any description of the company’s scale or market footprint must be derived solely from its classification as a pharmaceutical enterprise.
No explicit statements regarding subsidiaries, parent companies, or ownership structure are present in the provided material.

On September 9, 2022, Aarti Drugs was targeted in a ransomware attack carried out by the BianLian cybercriminal group.
The attackers exfiltrated approximately six gigabytes of sensitive data, encompassing employee records, financial documents, tax filings, and research information.
A ransom demand of twenty Bitcoin, equivalent to roughly ₹15.8 lakh at the time, was issued for the decryption keys.
Negotiations between the company and the attackers failed, resulting in the partial release of the stolen data on the dark web.
The BianLian ransomware variant used in the incident was developed in the Go programming language, which facilitates efficient payload execution and evasion of certain security controls.
Primary exploitation relied on unpatched Remote Desktop Protocol services, allowing the threat actors to gain initial access to the network.
The incident underscores that critical vulnerabilities often remain unpatched despite routine security audits, a challenge noted across the pharmaceutical industry.
Consequently, the event highlights the importance of robust patch management, network segmentation, and employee awareness training for organizations in the sector.

The available sources do not specify the ownership structure of Aarti Drugs, including whether it is publicly traded, privately held, or part of a larger conglomerate.
Likewise, no information is provided about any parent companies, subsidiaries, or joint ventures associated with the firm.